Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

Antimicrobial Agents and Chemotherapy
J B Schiff, J E Pennington

Abstract

The therapeutic efficacies of the newer beta-lactam antibiotics piperacillin, azlocillin and aztreonam were compared with the efficacies of ticarcillin and tobramycin in a guinea pig model of experimental Pseudomonas aeruginosa pneumonia. For animals challenged with 2 X 10(8) CFU, tobramycin treatment resulted in survival rates and intrapulmonary killing of pseudomonads which were significantly greater than those found with any of the beta-lactam agents. There were no significant differences noted among the individual beta-lactam agents. When animals were challenged with 200-fold-fewer organisms (10(6) CFU), there was no significant difference between the efficacy of tobramycin and those of the various beta-lactams. These data suggest that tobramycin is particularly valuable in treating more severe P. aeruginosa pneumonia, whereas a number of different beta-lactam agents are of equivalent value in less severe lung infections.

References

May 1, 1977·Antimicrobial Agents and Chemotherapy·D Stewart, G P Bodey
Sep 1, 1979·Infection and Immunity·J E Pennington, J J Miler
Dec 1, 1979·The Journal of Infectious Diseases·J E Pennington, R M Stone
Mar 1, 1978·Antimicrobial Agents and Chemotherapy·K P Fu, H C Neu
Oct 1, 1976·Antimicrobial Agents and Chemotherapy·A BroughtonG P Bodney
Dec 1, 1971·The Journal of Infectious Diseases·R E WintersW L Hewitt
Jan 1, 1982·Antimicrobial Agents and Chemotherapy·R B SykesN H Georgopapadakou
Mar 1, 1982·Reviews of Infectious Diseases·G M Eliopoulos, R C Moellering

❮ Previous
Next ❯

Citations

Mar 1, 1986·Antimicrobial Agents and Chemotherapy·B KemmerichJ E Pennington
Jul 15, 1985·The American Journal of Medicine·A L Baltch, R P Smith
Aug 1, 1988·Journal of Pharmacokinetics and Biopharmaceutics·J G ZhiR Quintiliani
Apr 29, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·B MarthaP Chavanet
Feb 1, 1995·Journal of Pharmaceutical and Biomedical Analysis·G La FolletteJ G Gambertoglio

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.